GLP-1 vs GIP: What the Difference Means for Your Weight Loss
Modern Weight Science Editorial Team
Editorial Team
Tirzepatide acts on two receptors — GLP-1 and GIP. Understanding what GIP does, and how the combination changes results, helps explain why the dual agonists have outperformed single-target drugs in trials.
Until tirzepatide arrived, all GLP-1 medications targeted a single receptor. Tirzepatide (Mounjaro, Zepbound) adds a second target — the GIP receptor — and the results in clinical trials have been meaningfully different. To understand why, it helps to know what each hormone actually does.
What GLP-1 does
GLP-1 (glucagon-like peptide-1) is released by your intestines after you eat. It stimulates insulin secretion, suppresses glucagon (which would otherwise push blood sugar higher), slows gastric emptying so food passes more gradually, and signals the brain to reduce hunger. GLP-1 receptor agonists work by activating these same pathways continuously — producing sustained appetite suppression and better blood sugar control.
What GIP does
GIP (glucose-dependent insulinotropic polypeptide) is a second gut hormone that also stimulates insulin release. Beyond that, GIP acts on fat tissue and the brain in ways researchers are still mapping. In the context of a GLP-1/GIP dual agonist, it appears to amplify appetite reduction and improve how the body handles fat — though the exact mechanism is not fully understood. Interestingly, GIP alone does not produce significant weight loss; the combination with GLP-1 is what creates the enhanced effect.
What the trial data shows
In head-to-head and comparative analyses, tirzepatide has generally produced greater average weight loss than semaglutide at the highest doses. The SURMOUNT-1 trial showed average weight loss of around 20–22% of body weight at the highest tirzepatide dose — compared to roughly 15% in the STEP-1 trial for semaglutide 2.4mg. These are averages across large populations; individual results vary considerably.
Does the difference matter for your choice?
Not always. The practical decision is often shaped by:
- Insurance coverage — what your plan actually covers
- Availability — whether your preferred drug is consistently in stock
- Tolerability — some people do better on one vs the other; you cannot know in advance
- Cost — both drugs have similar list prices; savings programs and formulary placement differ
The "mechanistically superior" drug is only better if you can access it consistently, tolerate it, and afford it long-term. That calculation is individual.
Drug selection is a clinical decision. The information here is for education — discuss which medication is appropriate for your situation with your prescriber.
About the author
Modern Weight Science Editorial Team
Editorial Team
Evidence-based research and educational content focused on metabolism, appetite regulation, and sustainable weight management. Our team synthesizes peer-reviewed research into clear, accessible guidance for informed health decisions.
Content reviewed against peer-reviewed research. Read our editorial policy →
Last updated May 2026
Frequently Asked Questions
What is GLP-1 and how does it work?
GLP-1 (glucagon-like peptide-1) is a hormone released by intestinal L-cells after eating. It stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and activates hypothalamic satiety pathways to reduce appetite. GLP-1 receptor agonist medications mimic these effects with a much longer duration — typically one week per injection.
How do GLP-1 medications cause weight loss?
GLP-1 receptor agonists reduce appetite through two pathways: peripheral (slowing gastric emptying extends fullness) and central (activating hypothalamic and brainstem receptors reduces hunger signaling and 'food noise'). The result is a sustained reduction in calorie intake without requiring active willpower against elevated hunger hormones.
What is the difference between semaglutide and tirzepatide?
Semaglutide (Ozempic, Wegovy) activates GLP-1 receptors only. Tirzepatide (Mounjaro, Zepbound) is a dual GLP-1/GIP agonist. Clinical trials show tirzepatide produces higher average weight loss (~20-22% in SURMOUNT-1 vs. ~15% for semaglutide in STEP 1), though individual response varies considerably depending on biology, dose, and adherence.
Are GLP-1 medications safe to use long-term?
The longest available randomized trial data (STEP 5 for semaglutide) shows maintained efficacy and tolerability over two years. Side effects are primarily gastrointestinal and concentrated during dose escalation. As with any prescription medication, long-term risks and benefits must be evaluated with a licensed clinician who knows your individual medical history.
Not medical advice. This guide is for general education only. GLP-1 medications, dosing, and treatment suitability are decisions for you and a licensed clinician who knows your full medical history.
Explore Modern GLP-1 Approaches
Telehealth platforms that connect patients with licensed clinicians to evaluate GLP-1 based care.
Ro Body
Licensed physicians review your medical history, discuss GLP-1 receptor agonist options, and provide ongoing monitoring — all remotely.
Explore approachHims & Hers
Connects patients with licensed clinicians who specialize in metabolic care, including evaluation for GLP-1 medications where appropriate.
Explore approachPlushCare
Board-certified physicians available for metabolic health consultations, with the ability to prescribe and monitor evidence-based treatments.
Explore approachAffiliate disclosure: Modern Weight Science may earn a commission if you visit or purchase through these links, at no additional cost to you. Programs are listed for educational relevance. This is not a clinical recommendation — always consult a licensed healthcare professional before starting any treatment.
Weekly Digest
Get Evidence-Based Metabolic Health Insights Weekly
Research-backed insights on metabolism, GLP-1 science, and sustainable weight management — once a week.
Continue reading
Related articles
What Is GLP-1? A Plain-Language Guide to How These Medications Work
GLP-1 stands for glucagon-like peptide-1 — a hormone your gut produces naturally after every meal. Understanding what it does, and how medications mimic it, explains almost everything about why these drugs work.
Sleep Quality on Semaglutide: What Patients Report
Better sleep is among the most-reported quality-of-life changes on semaglutide. Some of it is weight-mediated; some of it appears to be direct.
Foods to Avoid on GLP-1 Medications (and Why They Trigger Side Effects)
Slowed gastric emptying makes some foods feel worse than others. The list isn't long, but it's specific.
Not Losing Weight on Ozempic? 7 Reasons and What to Try
STEP 1 average: 14.9% loss at 68 weeks. But the range was wide — some lost over 25%, some less than 5%. Here are the most common explanations for being on the lower end of that distribution.